SCM Lifescience decides on paid-in capital increase
풍전약품
298060
Signal Score
Historical Avg Return (5d)
+0.38%
Data Coverage
100%n=2330
Risk-adjusted indicator based on 2330 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Discount Rate: 6%
- • Board Resolution Date: June 10, 2026
AI Analysis Summary
SCM Lifescience Co., Ltd. announced a decision on a paid-in capital increase via third-party allocation. The new shares will be issued at a 6% discount to the reference stock price, calculated based on regulations. The shares will be subject to a one-year lock-up period at Korea Securities Depository. The specific number of shares, issuance price, and funding amount are not yet disclosed, but the third-party allocation aims to achieve company management strategic objectives. This type of capital increase typically leads to dilution for existing shareholders.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.